Exclusive: Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys
The Food and Drug Administration announced the move, confirming an earlier Reuters report, after making the request at a meeting with Sarepta on Friday.
After the FDA request, Cambridge, Massachusetts-based Sarepta said in a statement that it will continue to ship the therapy to ambulatory people but maintain a halt it implemented June 15 for non-ambulatory patients after reporting to the FDA a case of acute liver failure in a patient who could not walk.
Sarepta said it made the decision "based on our comprehensive scientific interpretation of the data, which shows no new or changed safety signals in the ambulant patient population."
While the 51-year-old man with limb girdle muscular dystrophy who died most recently was not taking Elevidys, his experimental therapy and Elevidys are based on similar gene technology, the FDA said.
The FDA said it was putting clinical trials for limb girdle muscular dystrophy on hold due to safety concerns.
Elevidys received traditional approval in 2024 for patients age 4 and older with the Duchenne muscular dystrophy gene mutation who can walk, as well as accelerated, conditional approval for those with the muscle-wasting disease who cannot, even though the therapy failed to meet the main goal in a late-stage trial.
In another setback, the regulator also revoked the platform technology designation for Sarepta's gene therapy, a status that can streamline regulatory review and that is given when a technology has promise across multiple indications.
Sarepta shares ended down 36% at $14.08. At one point on Friday, the stock tumbled over 40% to a more than nine-year low after the company disclosed the third patient death.
The agency increased scrutiny of Sarepta when two teenage boys receiving Elevidys died this year. All three of the deaths were caused by acute liver failure and occurred in non-ambulatory patients.
The FDA said it is continuing to investigate the risk of acute liver failure with serious outcomes, including hospitalization and death, with gene therapies using Sarepta's AAVrh74 platform technology.
Wall Street analysts have said the third death could make patients more hesitant to use Elevidys. Patient groups said the developments around Elevidys have been concerning.
"Families with Duchenne muscular dystrophy are grappling with a mix of disappointment, concern...and uncertainty about choices they are making for their own children or themselves," said Debra Miller, founder of the non-profit CureDuchenne.
On Wednesday, Sarepta said it was working with the FDA to add a warning label about liver toxicity risks to Elevidys' packaging.
On an investor call on Friday, analysts asked Sarepta why it had not disclosed the latest patient death on Wednesday, when it announced 500 layoffs and cuts to its limb-girdle muscular dystrophy program, citing financial reasons.
CEO Doug Ingram said the matter was "neither material, nor central" to Wednesday's update and the decision to end the limb-girdle muscular dystrophy gene therapy study was made independently of the patient death.
The company also said liver issues were not a new safety signal in the study. However, some analysts, including those at BMO Capital Markets, warned that Sarepta's handling of the disclosure could damage management credibility.
At least two analysts asked whether other deaths had occurred in Sarepta's gene therapy programs. The company said it was not aware of any beyond the three that were disclosed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
an hour ago
- The Independent
One of the biggest microplastic pollution sources revealed – and it's not straws or bags
Every few years, the tires on your car wear thin and need to be replaced. But where does that lost tire material go? The answer, unfortunately, is often waterways, where the tiny microplastic particles from the tires' synthetic rubber carry several chemicals that can transfer into fish, crabs and perhaps even the people who eat them. We are analytical and environmental chemists who are studying ways to remove those microplastics – and the toxic chemicals they carry – before they reach waterways and the aquatic organisms that live there. Microplastics, macro-problem Millions of metric tons of plastic waste enter the world's oceans every year. In recent times, tire wear particles have been found to account for about 45% of all microplastics in both terrestrial and aquatic systems. Tires shed tiny microplastics as they move over roadways. Rain washes those tire wear particles into ditches, where they flow into streams, lakes, rivers and oceans. Along the way, fish, crabs, oysters and other aquatic life often find these tire wear particles in their food. With each bite, the fish also consume extremely toxic chemicals that can affect both the fish themselves and whatever creatures eat them. Some fish species, like rainbow trout, brook trout and coho salmon, are dying from toxic chemicals linked to tire wear particles. Researchers in 2020 found that more than half of the coho salmon returning to streams in Washington state died before spawning, largely because of 6PPD-Q, a chemical stemming from 6PPD, which is added to tires to help keep them from degrading. But the effects of tire wear particles aren't just on aquatic organisms. Humans and animals alike may be exposed to airborne tire wear particles, especially people and animals who live near major roadways. In a study in China, the same chemical, 6PPD-Q, was also found in the urine of children and adults. While the effects of this chemical on the human body are still being studied, recent research shows that exposure to this chemical could harm multiple human organs, including the liver, lungs and kidneys. In Oxford, Mississippi, we identified more than 30,000 tire wear particles in 24 liters of stormwater runoff from roads and parking lots after two rainstorms. In heavy traffic areas, we believe the concentrations could be much higher. The Interstate Technology and Regulatory Council, a states-led coalition, in 2023 recommended identifying and deploying alternatives to 6PPD in tires to reduce 6PPD-Q in the environment. But tire manufacturers say there's no suitable replacement yet. What can communities do to reduce harm? At the University of Mississippi, we are experimenting with sustainable ways of removing tire wear particles from waterways with accessible and low-cost natural materials from agricultural wastes. The idea is simple: Capture the tire wear particles before they reach the streams, rivers and oceans. In a recent study, we tested pine wood chips and biochar – a form or charcoal made from heating rice husks in a limited oxygen chamber, a process known as pyrolysis – and found they could remove approximately 90% of tire wear particles from water runoff at our test sites in Oxford. Biochar is an established material for removing contaminants from water due to its large surface area and pores, abundant chemical binding groups, high stability, strong adsorption capacity and low cost. Wood chips, because of their rich composition of natural organic compounds, have also been shown to remove contaminants. Other scientists have also used sand to filter out microplastics, but its removal rate was low compared with biochar. We designed a biofiltration system using biochar and wood chips in a filter sock and placed it at the mouth of a drainage outlet. Then we collected stormwater runoff samples and measured the tire wear particles before and after the biofilters were in place during two storms over the span of two months. The concentration of tire wear particles was found to be significantly lower after the biofilter was in place. The unique elongated and jagged features of tire wear particles make it easy for them to get trapped or entangled in the pores of these materials during a storm event. Even the smallest tire wear particles were trapped in the intricate network of these materials. Using biomass filters in the future We believe this approach holds strong potential for scalability to mitigate tire wear particle pollution and other contaminants during rainstorms. Since biochar and wood chips can be generated from agricultural waste, they are relatively inexpensive and readily available to local communities. Long-term monitoring studies will be needed, especially in heavy traffic environments, to fully determine the effectiveness and scalability of the approach. The source of the filtering material is also important. There have been some concerns about whether raw farm waste that has not undergone pyrolysis could release organic pollutants. Like most filters, the biofilters would need to be replaced over time – with used filters disposed of properly – since the contaminants build up and the filters degrade. Plastic waste is harming the environment, the food people eat and potentially human health. We believe biofilters made from plant waste could be an effective and relatively inexpensive, environmentally friendly solution. Boluwatife S. Olubusoye is a PhD Candidate in Chemistry at the University of Mississippi. James V. Cizdziel is a Professor of Chemistry at the University of Mississippi.
NBC News
an hour ago
- NBC News
FDA to review prescription fluoride supplements for kids at risk for tooth decay
The Trump administration is inching closer to banning fluoride tablets and drops often prescribed to kids who don't have access to fluoridated drinking water and are at high risk for mouths full of decayed teeth. On Wednesday, the Food and Drug Administration will host a public meeting featuring both supporters and opponents of fluoride supplements. While dentists overwhelmingly say the tablets have been used safely for decades, more than half of the meeting will be spent 'identifying safety concerns and potential risk' associated with the supplements. A final decision about whether to pull fluoride supplements off the market isn't expected until the end of October. In May, the FDA commissioner, Dr. Marty Makary, announced the agency's intention to get rid of them. Wednesday's meeting includes 18 speakers, including well-known fluoride skeptics like Dr. Bill Osmonsun, a retired dentist now with the Fluoride Action Network, and Dr. Bruce Lanphear, a professor of health sciences at Simon Fraser University in Canada. Lanphear published a controversial 2019 study suggesting that IQ levels were slightly lower in kids whose mothers had ingested more fluoride while pregnant, research that's frequently cited by Health Secretary Robert F. Kennedy Jr. Dr. Charlotte Lewis, a professor of pediatrics at the University of Washington School of Medicine, and Dr. Jayanth Kumar, who previously was dental director for California, will counter those presentations. Dr. James Bekker, a pediatric dentist and a member of the Utah Dental Association who is scheduled to speak at Wednesday's meeting, said: 'Say we take supplements off the market. What's the alternative? There is none.' Utah and Florida have banned fluoride from public water systems. Similar legislation is under consideration in Kentucky, Massachusetts and Nebraska. Critics say the risks from fluoride during a child's early years override the benefit of protecting against tooth decay, a disease that can cause pain, infection and other possible health problems. In an interview with Fox News, Kennedy acknowledged that areas without fluoride in their water are likely to have 'slightly more cavities.' Bekker was more blunt. 'Buckle up,' he said. 'We're going to have an onslaught of cavities.' What are fluoride supplements? Nearly two-thirds of dentists in the United States prescribe fluoride supplements to their patients, especially in areas without community water fluoridation, according to a American Dental Association report this year. Sodium fluoride tablets and drops are prescription only, and they have been used for decades to prevent tooth decay. A 2011 analysis of 11 studies, including some randomized controlled trials, by French researchers found that 0.25 mg up to 1 mg a day of the supplements reduced rates of cavities in kids by nearly a quarter. The chewable tablets come in several doses and are particularly important for families who live in areas without fluoride in drinking water and who don't have dental insurance or can't afford regular visits to dentists. Even though Medicaid covers oral health for children, fewer than half went to the dentist at least once a year. Cavities that erupt in those kids get worse if they're left untreated, and they can cause widespread damage. The decay 'eats away at the bone' around the tooth and sometimes gets into the bloodstream, said Dr. Steven Levy, a professor of preventive and community dentistry at the University of Iowa. 'This is more than just a garden-variety, middle-class person's experience with a cavity,' he said. Major public health groups, including the American Academy of Pediatrics and the U.S. Preventive Services Task Force, recommend prescribing supplements for children starting at 6 months if the water supply isn't fluoridated. Fluoride supplements are often given to kids from age 5 until they have their permanent teeth, around age 13 or 14, Bekker said. Babies get drops until they're old enough to chew tablets. They're generally inexpensive. Over-the-counter vitamins and supplements don't contain fluoride. Fluoride is available over the counter only in toothpaste and mouthwashes. Limited research on fluoride supplements According to Makary, the FDA commissioner, ingested fluoride alters the gut microbiome. That assertion appears to hinge on a 2023 review of research on the matter. Scientists in Ireland noted that animal studies suggested ingesting fluoride affected the microbiome but that none of the studies examined fluoride and the human microbiome. They concluded that any possible effect of fluoride on the microbiome is 'still in its early days, and studies investigating the impact of fluoride on the human microbiome have only begun to appear in the literature.' Makary also objects to the fluoride supplements because they aren't approved by the FDA. Because the supplements had been in use for decades before Congress mandated that drug manufacturers show that their products were not only safe but also effective, they were never required to go through the approval process. For almost as long as the supplements have been prescribed, critics have been concerned about the lack of rigorous data showing their potential health effects and how they protect kids' teeth. 'I think we really need to understand the benefits,' said Linda Birnbaum, a toxicologist and former director of the National Institute of Environmental Health Sciences and the National Toxicology Program. Birnbaum is listed as a speaker at the FDA meeting Wednesday. 'Why is this even a question? This is the biggest no-brainer since sliced bread,' he said.
Daily Mail
an hour ago
- Daily Mail
Breakthrough for MALE birth control pill: Experimental hormone–free tablet passes its first safety test in men
For decades, the responsibility of taking a birth control pill has been placed firmly on the shoulders of women. But that could soon change – as an experimental pill for men that works by blocking sperm production has just passed its first safety test in humans. The hormone–free contraceptive tablet, called YCT–529, has already been found to prevent 99 per cent of pregnancies during experiments in mice. It works by blocking access to vitamin A in the testes, preventing sperm production without affecting testosterone levels – meaning libido is not impacted. The male pill, which experts hope will be available this decade, is the only one currently being tested in humans. For the latest trial, researchers recruited 16 men who were put on different doses of the pill across several days. Instead of testing how effective it was in humans – all of the men had undergone vasectomies – the aim was to discover if there were any side–effects. Analysis revealed there were no concerning changes in heart rate, hormone function, inflammation, mood or sexual function. Next, the team will test the pill in larger trials that will look at how effective it is in preventing sperm production in humans. The results of the safety trial, published in the journal Communications Medicine, are a critical first step toward getting the pill approved, experts said. 'We really need more reversible contraceptive methods for men,' Dr Stephanie Page, an endocrinologist at the University of Washington School of Medicine and who wasn't involved in the study, told Scientific American. Currently, the other male birth control options are vasectomies – a surgical procedure that involves cutting and sealing the tubes that carry sperm from the testicles – or condoms. Vasectomies, also known as 'the snip', can be reversed but the success rate of reversal procedures vary widely. Earlier tests in male primates also found the drug lowered sperm counts within just two weeks. Crucially, both mice and non–human primates fully regained fertility after stopping the drug and no side effects were detected in either species. Mice regained fertility within six weeks, while non–human primates fully recovered their sperm count in 10 to 15 weeks. How does it work? Researchers have understood for decades that vitamin A is essential for male fertility. YCT–529 is a retinoic acid receptor–alpha (RAR–a) inhibitor that prevents production of sperm cells in the testes as well as their release. It does this by blocking RAR–alpha – one of three nuclear receptors that bind retinoic acid, a form of vitamin A. YCT–529 is being worked on as part of a collaboration between University of Minnesota College of Pharmacy, Columbia University in New York and San Francisco–based firm YourChoice Therapeutics. 'A safe and effective male pill will provide more options to couples for birth control,' Gunda Georg, chemist and pharmacist at the University of Minnesota, said earlier this year. 'It will allow a more equitable sharing of responsibility for family planning and provide reproductive autonomy for men.' Both the animal studies and the human trial results suggest that the approved pill would likely be taken once a day, but further trials will confirm that dosing. 'The positive results from this first clinical trial laid the groundwork for a second trial, where men receive YCT–529 for 28 days and 90 days, to study safety and changes in sperm parameters,' the study authors wrote in their paper, published in the journal Communications Medicine. Currently, around a quarter of women who use contraception take an oral birth control pill, but there are no equivalent methods available for men. If the male pill proves to be as effective in humans as it is in mice, it would be on a par with the female birth control medication. Lead author and YourChoice Therapeutics' Chief Science Officer Nadja Mannowetz said: 'A peer–reviewed publication for our first–in–human study reinforces YCT–529's strong safety profile. 'It also shows "the Pill for men" had no effect on sexual desire or mood.' Nearly half of all pregnancies globally are unintended, suggesting an urgent need for more male contraceptive options. There is also high demand for new methods. A recent study showed men are very interested in using new male contraceptive options and women are confident they'll take them correctly. 'Studies and surveys continue to show that men want to share the burden of pregnancy prevention with their partners,' Akash Bakshi, CEO of YourChoice Therapeutics, said. 'But they have just one non–permanent contraceptive option—condoms—and it's 170 years old. Innovation is long overdue. 'Data show men favour an oral contraceptive and one that's hormone–free, positioning YCT–529 as potentially transformative for a healthcare segment that's been stagnant for more than a century and a half.' Women have several birth control options available including short–term rapid methods like birth control pills and patches and a contraceptive cap or diaphragm. They also have long–term options such as implants, which produce hormones that stop the release of an egg. Some opt for an intrauterine device – a T–shaped device placed into the uterus to prevent an egg from implanting. The birth control pill or patches are about 93 per cent effective at preventing pregnancies. However long–term devices like the intrauterine device are more than 99 per cent effective. There have been few changes in male contraception compared with the range of options available to women. Although there's ongoing research into a male contraceptive pill, there is not one available yet. At the moment, the 2 contraceptive methods available to men are: Condoms – a barrier form of contraception that stops sperm from reaching and fertilizing an egg Vasectomy – a minor, usually permanent, surgical procedure that stops sperm from reaching the semen ejaculated from the penis The withdrawal method of taking your penis out of your partner's vagina before ejaculating is not a method of contraception. This is because sperm can be released before ejaculation and cause pregnancy.
